Company intelligence / Profile preview
Novatim Immune Therapeutics
Hangzhou, Zhejiang, Chinaen.novatim-zj.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Novatim has advanced a pipeline of first-in-class and best-in-class immunotherapies targeting solid tumors and hematological malignancies. Its lead asset KY‑0301 is the world’s first nanobody-based bispecific ADC targeting c-MET and EGFR in Phase 1/2 trials in advanced solid tumors. Preclinical data show strong tumor penetration and safety. Multiple CAR-T programs are in early clinical or preclinical stages.
- Therapeutic areas
- OncologyImmunologyHematology
- Modalities
- Antibody-drug conjugateMonoclonal antibodyNanobody therapyCAR-T cell therapyFusion protein
- Industry
- Biotech
02
Drug pipeline
9 assets8 more assets in the full pipeline.
03
Partnerships
SDM Bioservices—regulatory support for FDA/NMPA IND submissions for KY–0301
Beyond the preview
Go deeper on Novatim Immune Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novatim Immune Therapeutics.